Telephone sharing button Contact Us mailbox sharing button
arrow_left sharing button
arrow_right sharing button

药明合联2023年业绩表现强劲,营收高速增长114%, 卓越业绩铸就未来发展根基和优势

营业收入强劲增长114%至21.24 亿元人民币 经调整净利润强劲增长112%至4.12 亿元人民币 综合项目数升至 143 个 新签订50个综合项目 临床II期和III期项目数增至21个,包括 5 个生产工艺验证(PPQ) 项目,为未来潜在商业化增长铸就强大动力 储备订单增长 82%至 5.79 亿美元,为公司维持高速增长势头打下基础 “一站式”生产设施在无锡基地成功投入运营,同园区偶联生产布局高效提升产能和规模 成功在香港交易所主板上市,总募集资金 5.2 亿美元,获评「IFR 亚洲」评选“最佳IPO” 荣膺「World...

WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development

SHANGHAI, Jan 31, 2024—WuXi XDC (2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market; and Multitude Therapeutics, a clinical stage biotechnology company renowned for...

You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?